# Trade Mark Journal No.2026/006 6 February 2026

## UK00004327821 21 January 2026 (5)

International priority date claimed: 17 November 2025 (United States of America) (99500529)

Class 5
  Bioavailability enhancing molecular complex as an intermediate product in the manufacture of pharmaceuticals for the treatment of migraines, neurological disorders and central nervous system disorders.

Axsome Therapeutics, Inc.

Representative: Keltie LLP